In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Hologic (HOLX – Research Report), with a price target of $70.00. The company’s shares closed last Thursday at $71.10.
According to TipRanks.com, Savant is a 1-star analyst with an average return of -5.9% and a 42.5% success rate. Savant covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Pacific Biosciences, and Akoya Biosciences.
Hologic has an analyst consensus of Moderate Buy, with a price target consensus of $76.60, an 8.8% upside from current levels. In a report issued on July 20, UBS also initiated coverage with a Hold rating on the stock with a $73.00 price target.
The company has a one-year high of $81.04 and a one-year low of $66.58. Currently, Hologic has an average volume of 1.96M.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HOLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
Read More on HOLX:
- RBC Capital Reaffirms Their Buy Rating on Fortune Brands (FBHS)
- Fortune Brands (FBHS) Gets a Buy Rating from UBS
- Danaher (DHR) Received its Third Buy in a Row
- Morgan Stanley Sticks to Its Hold Rating for Cognizant (CTSH)
- Analysts Offer Insights on Consumer Goods Companies: O’Reilly Auto (ORLY) and Sleep Number (SNBR)